Blood pressure control in hypertension. Pros and cons of available treatment strategies

Journal of Hypertension

Volumn 35, Issue 2, 2017, Pages 225-233

  Mancia, Giuseppe ^a,b   Rea, Federico ^c   Cuspidi, Cesare ^a,b   Grassi, Guido ^a,d   Corrao, Giovanni ^c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c Epidemiology and Public Health   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

Author keywords

Blood pressure control; Cardiovascular prevention; Combination treatment; Hypertension

Indexed keywords

PRESCRIPTION DRUG; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MEDICAL PRACTICE; MEDICATION COMPLIANCE; MONOTHERAPY; PATIENT RISK; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BLOOD PRESSURE; CLINICAL PRACTICE; COMBINATION DRUG THERAPY; DRUG EFFECTS; PATHOPHYSIOLOGY; UTILIZATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PRACTICE PATTERNS, PHYSICIANS';

EID: 85000786926     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001181     Document Type: Review

References (76)

1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
2. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
3. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al., PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310:959-968.
4. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22:11-19.
5. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 2004; 22:435-445.
6. Banegas JR, Segura J, Sobrino J, Rodriguez-Artalejo F, De la Sierra A, De la Cruz JJ, et al., Spanish Society of Hypertension Ambulatory Blood Pressure Monitoring Registry Investigators. Effectiveness of blood pressure control outside the medical setting. Hypertension 2007; 49:62-68.
7. Mancia G, Ambrosioni E, Rosei EA, Leonetti G, Trimarco B, Volpe M, ForLife study group. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005; 23:1575-1581.
8. Mancia G, Agabiti-Rosei E, Cifkova R, DeBacker G, Erdine S, Fagard R, et al. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
9. Ezzati M, Riboli E. Behavioral and dietary risk factors for noncommu-nicable diseases. N Engl J Med 2013; 369:954-964.
10. Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007; 25:1491-1497.
11. Benetos A, Thomas F, Bean KE, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21:1635-1640.
12. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008; 26:819-824.
13. Banegas JR, Segura J, Ruilope LM, Luque M, Garcia-Robles R, Campo C, et al., CLUE Study Group Investigators. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43:1338-1344.
14. Chobanian AV, Bakris G, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on prevention, detection evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560-2672.
15. Piepoli MF, Hoes AW, Agewall S, Albus S, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37:2315-2381.
16. WHO Expert Committee. Arterial hypertension. Geneva: World Health Organization; 1978; Tech Rep Series.
17. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427.
18. Ambrosioni E, Leonetti G, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18:1691-1699.
19. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610-618.
20. Corrao G, Rea F, Ghirardi A, Soranna D, Merlino L, Mancia G. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015; 66:742-749.
21. Corrao G, Mazzola P, Monzio Compagnoni M, Rea F, Merlino L, et al. Antihypertensive medications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81, 617 Italian patients newly treated between 2005 and 2009. Drugs Aging 2015; 32:927-936.
22. Mancia G, Stella ML, Pozzi M, Grassi G. Treatment of hypertension: general aspects. J Cardiovasc Pharmacol 1996; 28 (suppl. 4):S23-S28.
23. Mancia G, Grassi G, Zanchetti A. Antihypertensive treatment and blood pressure in diabetic and nondiabetic patients. The lower, the better? Diabetes Care 2011; 34:S304-S307.
24. Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001; 14:241-247.
25. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11, 000 participants from 42 trials. Am J Med 2009; 122:290-300.
26. Mancia G, van Zwieten PA. Antihypertensive treatment strategies. In: Mancia G, Grassi G, Redon J, editors. in Manual of Hypertension of the European Society of Hypertension, 2nd edn. London: Taylor and Francis; 2014. pp. 93-100; Chapter 10.
27. Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens 2001; 19 (suppl):S33-S40.
28. Hirakawa Y, Arima H, Webster R, Zoungas S, Li Q, Harrap S, et al. Risk associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes. J Hypertens 2016; 34:781-787.
29. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
30. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al., ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367:2204-2213.
31. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihyper-tensive drugs. J Hypertens 2006; 24:3-10.
32. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-3972.
33. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Low-ering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
34. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
35. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al., ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4:393-404.
36. Kjeldsen SE, Messerli FH, Chiang CE, Meredith PA, Liu L. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin 2012; 28:1685-1697.
37. Toth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients) study. Am J Cardio-vasc Drugs 2014; 14:137-145.
38. Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y, et al. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 2014; 63:259-264.
39. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al., British Hypertension Society's PATHWAY Studies Group. Spironolactone versus palcebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomized, double-blind, crossover trial. Lancet 2015; 386:2059-2068.
40. Weber MA, Julius S, Kjeldsen SE, Jia Y, Brunner HR, Zappe DH, Hua TA, et al. Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. J Hypertens 2012; 30:2213-2222.
41. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
42. Mancia G, Grassi G. Aggressive blood pressure lowering is dangerous: the J-curve. Pro-side of the argument. Hypertension 2014; 63:29-36.
43. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.
44. Mancia G, Kjeldsen SE, Zappe DH, Holzhauer B, Hua T, Zanchetti A, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J 2016; 37:955-964.
45. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels-updated overview and meta-analyses of randomized trials. J Hypertens 2016; 34:613-622.
46. SPRINT Research GroupWright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood pressure control. N Engl J Med 2015; 373:2103-2116.
47. Lonn EM, Bosch J, Lopez-Jaramillo P, López-Jaramillo P, Zhu J, Liu L, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374:2009-2020.
48. Mancia G, Asmar R, Amodeo C, Mourad JJ, Taddei S, Gamba MA, et al. Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens 2015; 33:401-411.
49. Mancia G, Parati G, Bilo G, Choi J, Kilama MO, Ruilope LM, TALENT investigators. Blood pressure control by the nifedipine GITS-telmisar-tan combination in patients at high cardiovascular risk: the TALENT study. J Hypertens 2011; 29:600-609.
50. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a random-ised, parallel-group trial. Lancet 2011; 377:312-320.
51. Mancia G, Coca A, Chazova I, Girerd X, Haller H, et al., FELT investigators. Effects on office and home blood pressure of the lerca-nidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial. J Hypertens 2014; 32:1700-1707.
52. Neutel JM, Mancia G, Black HR, Dahlöf B, Defeo H, Ley L, Vinisko R, TEAMSTA Severe HTN Study Investigators. Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich) 2012; 14:206-215.
53. Kjeldsen SE, Sica D, Haller H, Cha G, Gil-Extremera B, Harvey P, et al., DISTINCT Investigators. Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. J Hypertens 2014; 32:2488-2498.
54. Effects morbidity of treatment on in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213:1143-1152.
55. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet 1980; 1:1261-1267.
56. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255-3264.
57. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
58. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985; 291:97-104.
59. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of anti-hypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051.
60. Mancia G. Comparison of a new first-line single-pill antihypertensive strategy with a stepped-care strategy using the time to blood pressure control 25th European Meeting on Hypertension and Cardiovascular Protection. J Hypertens 2015; 33 (e-suppl 1); [abstract PP.07.22].
61. Mourad JJ, Waeber B, Zannad F, Laville M, Duru G, Andréjak M, investigators of the STRATHE trial. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004; 22:2379-2386.
62. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SAE, Feagan BG. A simplified approach to the treatment of uncomplicated hyper-tension. a cluster randomized controlled trial. Hypertension 2009; 53:6464-6653.
63. Gradman AH, Paris H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61:309-318.
64. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59:1124-1131.
65. Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens 2014; 32:1708-1715.
66. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28:1584-1590.
67. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive mono-therapy in 13 managed care organizations. J Manag Care Pharm 2006; 12:239-245.
68. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15.
69. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43:521-530.
70. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120:1598-1605.
71. Corrao G, Nicotra F, Parodi A, Zambon A, Heiman F, Merlino L, et al. Cardiovascular protection by initial and subsequent combinationof anti-hypertensive drugs in daily life practice. Hypertension 2011; 58:566-572.
72. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med 2004; 116 (Suppl 5A):30S-38S.
73. Giannattasio C, Cairo M, Cesana F, Alloni M, Sormani P, Colombo G, et al. Blood pressure control in Italian essential hypertensives treated by general practitioners. Am J Hypertens 2012; 25:1182-1187.
74. Mancia G, Pessina AC, Trimarco B, Grassi G, SILVIA (Studio Italiano Longitudinale sulla Valutazione della Ipertensione Arteriosa nel 2000) Study Group. Blood pressure control according to new guidelines targets in low-to high-risk hypertensives managed in specialist practice. J Hypertens 2004; 22:2387-2396.
75. Mancia G, Parati G, Borghi C, Ghironzi G, Andriani E, Marinelli L, et al., SMOOTH investigators. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino popu-lation: the SMOOTH study. J Hypertens 2006; 24:837-843.
76. Borghi C, Dormi A, D'Addato S, Gaddi A, Ambrosioni E, Brisighella Heart Study Working Party. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004; 22:1707-1716.